Novo Nordisk Targets 'Obesity Disease Market' Despite Commercial Doubts
Novo Nordisk is targeting obesity as a key disease market, but its CEO says global alliances are needed in future to help fight the global pandemic, including the food industry.
You may also be interested in...
The head of AstraZeneca's newly combined cardiovascular, metabolic diseases and renal franchise says his mission is to align and find synergies for the three therapeutic areas.
Sweden´s ecosystem for drug discovery and development is flourishing, seeded by academia, nurtured by incubators and funded from varied sources, 2020 report shows.
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.